Patient P-02136
Synthetic patientMETA-24 · Day 180 · 65–74 · M · baseline S10Steering view · 3DOpen companion preview
Therapy response
Favorable
Tolerance
Improving
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
71%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S10
- Day 50 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 122 CR-01 recommended — Clinician Review CR-01
- Day 123 Patient declined — Not now
What changed?
Trajectory began diverging from predicted response on Day 50.
Primary contributors, last 14 days
- GI instability+9
- Toxicity-6
- Inflammatory activity+3
- Treatment adherence-3
- Nutritional resilience-2
What helped?
- Clinician Review CR-01Day 122Declined by patient
LIFE OS recommendation
GI Support Protocol GI-04
69%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 89% showed improvement
- median effect visible after 8 days
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Active minutes
Wearable19 min
worsening · -2.4 vs previous 14 d
Sleep duration
Wearable5.4 h
stable · +0.0 vs previous 14 d
Energy level
Daily log2.8/10
worsening · -0.2 vs previous 14 d
Steps
Wearable2,663
worsening · -158 vs previous 14 d
GI burden
Companion61.7/100
worsening · +3.8 vs previous 14 d
Adherence
Companion59.6 %
worsening · -5.5 vs previous 14 d
Sleep quality
Wearable8/100
stable · +0.4 vs previous 14 d
Glucose, CGM daily mean
CGM146 mg/dL
stable · -2.0 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards failing · 40 from the failing basin, 60 from restoration.
Would help
- GI-04 GI Support Protocol77% improved among 64 similar · onset 8 d · confidence 64%
- ME-01 Monitoring Escalation100% improved among 42 similar · onset 3 d · confidence 74%
- NP-02 Dietary Support Protocol59% improved among 32 similar · onset 10 d · confidence 74%
- More proteinGI -5.3 next day on high-intake days · n 20
Would not help
- Keep fat lowGI +5.6 next day on high-intake days · n 15
- Keep ultra-processed lowGI +3 next day on high-intake days · n 19
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Dietary fat load+5.6detractor · 95%
- Protein-5.3supporter · 95%
- Ultra-processed food+3detractor · 73%
- Histamine load+2.5no signal · 45%
- Simple carbohydrates+1.4no signal · 29%
- Insoluble fibre+0.8no signal · 19%
- Caffeine-0.4no signal · 15%
- Alcohol-0.2no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Inflammatory signalling ↑85
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 60
- WearableHRV 15 ms, trending down
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 33/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Mucosal barrier integrity ↓60
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 62 and rising
- WearableSleep 5.4 h, below personal baseline
- Autonomic recovery ↑40
- Wearable2,663 steps/day
- WearableShort sleep window
- Drug metabolism and exposure ↑20
- BloodToxicity index 52
DNA
Fictional pharmacogenomic panel
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Normal metabolizerExpected exposure
Microbiome
Shannon diversity 3.1 · butyrate capacity 33/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisHigh
- Bifidobacterium longumNormal
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 16 ms
- Sleep
- 5.6 h
- Steps
- 2,922
- Resting HR
- 73 bpm
Daily log: GI score 62, nutritional resilience 34, adherence 60.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.